Страна: Німеччина
мова: англійська
Джерело: HMA (Heads of Medicines Agencies)
buprenorphine hydrochloride 0.32 mg
Animalcare Limited
QN02AE01
Solution for injection
buprenorphine
Cats, Dogs
2008-02-15
Revised: June 2013 AN. 00507/2012 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Buprecare 0.3 mg/ml Solution for Injection for Dogs and Cats (UK, BE, FR, IE, LU, NL, ES) Buprenovet 0.3 mg/ml Solution for Injection for Dogs and Cats (AT, DE) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Each ampoule contains: Buprenorphine 0.3 mg/ml as buprenorphine hydrochloride. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs and cats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Dog Post-operative analgesia. Potentiation of the sedative effects of centrally-acting agents. Cat Post-operative analgesia. 4.3 CONTRAINDICATIONS The product should not be used pre-operatively for caesarean section (see Section 4.7). Do not use in case of hypersensitivity to the active substance or to any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS Revised: June 2013 AN. 00507/2012 Page 2 of 6 Buprenorphine may occasionally cause significant respiratory depression and, as with other opioid drugs, care should be taken when treating animals with impaired respiratory function or animals that are receiving drugs that can cause respiratory depression. Buprenorphine should be used with caution in animals with impaired liver function, especially biliary tract disease, as the substance is metabolised by the liver and its intensity and duration of ac Прочитайте повний документ